Mitchell McLeod Pugh & Williams’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.67M | Buy |
69,337
+25,764
| +59% | +$674K | 0.2% | 94 |
|
|
2026
Q1 | $1.22M | Buy |
43,573
+5,134
| +13% | +$137K | 0.18% | 110 |
|
|
2025
Q4 | $1.05M | Sell |
38,439
-3,392
| -8% | -$85.5K | 0.15% | 122 |
|
|
2025
Q3 | $1.02M | Sell |
41,831
-485
| -1% | -$12K | 0.16% | 114 |
|
|
2025
Q2 | $1.03M | Buy |
42,316
+7,859
| +23% | +$183K | 0.19% | 109 |
|
|
2025
Q1 | $873K | Buy |
34,457
+1,331
| +4% | +$34.8K | 0.18% | 119 |
|
|
2024
Q4 | $879K | Buy |
33,126
+324
| +1% | +$8.79K | 0.18% | 113 |
|
|
2024
Q3 | $949K | Buy |
32,802
+162
| +0.5% | +$4.73K | 0.2% | 113 |
|
|
2024
Q2 | $913K | Buy |
32,640
+36
| +0.1% | +$991 | 0.21% | 109 |
|
|
2024
Q1 | $905K | Sell |
32,604
-657
| -2% | -$18.2K | 0.22% | 109 |
|
|
2023
Q4 | $958K | Sell |
33,261
-1,797
| -5% | -$54.3K | 0.25% | 93 |
|
|
2023
Q3 | $1.16M | Buy |
35,058
+16
| +0% | +$566 | 0.34% | 74 |
|
|
2023
Q2 | $1.29M | Buy |
35,042
+3
| +0% | +$117 | 0.37% | 68 |
|
|
2023
Q1 | $1.43M | Buy |
35,039
+83
| +0.2% | +$3.58K | 0.44% | 59 |
|
|
2022
Q4 | $1.79M | Buy |
34,956
+978
| +3% | +$46.9K | 0.61% | 38 |
|
|
2022
Q3 | $1.49M | Buy |
33,978
+222
| +0.7% | +$10.8K | 0.57% | 48 |
|
|
2022
Q2 | $1.77M | Sell |
33,756
-371
| -1% | -$18.9K | 0.69% | 33 |
|
|
2022
Q1 | $1.77M | Buy |
34,127
+661
| +2% | +$34.3K | 0.59% | 46 |
|
|
2021
Q4 | $1.98M | Buy |
33,466
+500
| +2% | +$24.8K | 0.65% | 44 |
|
|
2021
Q3 | $1.42M | Hold |
32,966
| – | – | 0.53% | 55 |
|
|
2021
Q2 | $1.29M | Buy |
32,966
+807
| +3% | +$31.4K | 0.5% | 56 |
|
|
2021
Q1 | $1.17M | Buy |
32,159
+1,084
| +3% | +$38.5K | 0.49% | 58 |
|
|
2020
Q4 | $1.14M | Sell |
31,075
-1,695
| -5% | -$62.2K | 0.53% | 56 |
|
|
2020
Q3 | $1.14M | Buy |
32,770
+1,987
| +6% | +$69.7K | 0.58% | 51 |
|
|
2020
Q2 | $955K | Buy |
30,783
+12,651
| +70% | +$430K | 0.54% | 58 |
|
|
2020
Q1 | $562K | Sell |
18,132
-4,417
| -20% | -$151K | 0.43% | 78 |
|
|
2019
Q4 | $838K | Buy |
22,549
+242
| +1% | +$8.62K | 0.53% | 64 |
|
|
2019
Q3 | $760K | Buy |
22,307
+1,734
| +8% | +$63.1K | 0.51% | 64 |
|
|
2019
Q2 | $846K | Sell |
20,573
-872
| -4% | -$34.6K | 0.58% | 61 |
|
|
2019
Q1 | $864K | Buy |
21,445
+1,299
| +6% | +$52K | 0.6% | 59 |
|
|
2018
Q4 | $834K | Buy |
20,146
+116
| +0.6% | +$4.82K | 0.67% | 50 |
|
|
2018
Q3 | $838K | Sell |
20,030
-14
| -0.1% | -$539 | 0.56% | 56 |
|
|
2018
Q2 | $690K | Buy |
20,044
+1,249
| +7% | +$42.7K | 0.49% | 74 |
|
|
2018
Q1 | $632K | Sell |
18,795
-330
| -2% | -$11.3K | 0.45% | 80 |
|
|
2017
Q4 | $658K | Buy |
19,125
+330
| +2% | +$11.3K | 0.45% | 82 |
|
|
2017
Q3 | $636K | Sell |
18,795
-425
| -2% | -$13.7K | 0.47% | 82 |
|
|
2017
Q2 | $612K | Buy |
19,220
+2
| +0% | +$63 | 0.46% | 82 |
|
|
2017
Q1 | $624K | Buy |
19,218
+3
| +0% | +$95 | 0.49% | 71 |
|
|
2016
Q4 | $592K | Buy |
19,215
+1,609
| +9% | +$49.1K | 0.48% | 73 |
|
|
2016
Q3 | $566K | Buy |
17,606
+1
| +0% | +$33 | 0.5% | 74 |
|
|
2016
Q2 | $588K | Buy |
17,605
+3,259
| +23% | +$104K | 0.53% | 69 |
|
|
2016
Q1 | $403K | Buy |
14,346
+173
| +1% | +$4.94K | 0.39% | 92 |
|
|
2015
Q4 | $434K | Buy |
14,173
+948
| +7% | +$29.8K | 0.43% | 87 |
|
|
2015
Q3 | $394K | Hold |
13,225
| – | – | 0.41% | 88 |
|
|
2015
Q2 | $421K | Buy |
13,225
+140
| +1% | +$4.56K | 0.39% | 94 |
|
|
2015
Q1 | $432K | Sell |
13,085
-4
| -0% | -$127 | 0.39% | 91 |
|
|
2014
Q4 | $387K | Buy |
+13,089
| New | +$375K | 0.36% | 101 |
|
Other funds holding PFE
Mitchell McLeod Pugh & Williams's PFE Position: Q2 2026 in Review
Mitchell McLeod Pugh & Williams increased its Pfizer (PFE) stake by 59% in Q2 2026, buying an estimated $674K and bringing the position to 69,337 shares worth $1.67M. The position accounts for 0.2% of the portfolio, ranked #94.
Mitchell McLeod Pugh & Williams first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $1.98M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Mitchell McLeod Pugh & Williams held 69,337 shares of Pfizer worth $1.67M as of Q2 2026.
- Mitchell McLeod Pugh & Williams bought 25,764 Pfizer shares in Q2 2026, an estimated $674K.
- Pfizer made up 0.2% of Mitchell McLeod Pugh & Williams's portfolio in Q2 2026, its #94 holding.
- Mitchell McLeod Pugh & Williams first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
- Mitchell McLeod Pugh & Williams's Pfizer position peaked at $1.98M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Mitchell McLeod Pugh & Williams's 13F filing for Q2 2026, filed 11 Aug 2026.